Glioma Clinical Trials in Los Angeles, California

4 studies are recruiting for glioma in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

   The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following ques…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Locations

   30 in total

   Run by

   Black Diamond Therapeutics, Inc.

   See if you can join NCT07326566 on ClinicalTrials.gov

2. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

   This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of California, Los Angeles, Los Angeles, California

   Locations

   61 in total

   Run by

   Nuvation Bio Inc.

   See if you can join NCT05303519 on ClinicalTrials.gov

3. ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

   This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-fr…

   Stage

   Phase 3

   Ages

   Any age

   Site

   Kaiser Permanente Los Angeles Medical Center, Los Angeles, California

   Locations

   162 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT05580562 on ClinicalTrials.gov

4. Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

   This phase I trial studies how well zirconium (Zr)-89 crefmirlimab berdoxam and immuno-positron emission tomography (PET) identifies areas of immune cell activity in patients with brain tumors that can be removed by surgery (resectable). One important predictor of the immune response is the presenc…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT06650163 on ClinicalTrials.gov